Bauer T et al. Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study. WCLC 2024;Abstract MA06.08.
Besse B et al. Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours. ESMO 2024;Abstract 1256MO.
Camidge DR et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol 2024;42(25):3000-11. Abstract
Cho BC et al. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Lung Cancer 2024;188:107442. Abstract
Drilon AE at al. Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours. ESMO 2024;Abstract 1253O.
Drilon AE et al. Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies. ASCO 2024;Abstract 8522.
Fujiwara Y et al. Efficacy and safety of olomorasib with pembrolizumab + chemotherapy as first-line treatment in patients with KRAS G12C-mutant advanced NSCLC. WCLC 2024;Abstract OA14.04.
Heymach JV et al. Zongertinib in previously treated HER2-mutant non–small-cell lung cancer. N Engl J Med 2025;[Online ahead of print]. Abstract
Hill L et al. Predictors of long-term ensartinib response from the eXalt3 trial. WCLC 2024;Abstract MA06.09.
Horinouchi H et al. ALINA safety results; adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC). WCLC 2024;Abstract OA13.04.
Janne PA et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. ASCO 2024;Abstract 8543.
Le X et al. Safety and efficacy of BAY 2927088 in patients with HER2-mutant NSCLC: Expansion cohort from the phase I/II SOHO-01 study. WCLC 2024;Abstract PL04.03.
Lin JJ et al. Updated efficacy, safety, and biomarker analysis in patients with TRK fusion lung cancer treated with larotrectinib. WCLC 2024;Abstract MA06.12.
Liu G et al. Efficacy and safety of taletrectinib in patients with ROS1+ non-small cell lung cancer: The global TRUST-II study. WCLC 2024;Abstract MA06.03.
Mok TSK et al. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. ASCO 2024;Abstract LBA8509.
Nützinger J et al. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future. Lung Cancer 2023;186:107385. Abstract
Pérol M et al. CNS protective effect of selpercatinib in first-line RET fusion-positive advanced non-small cell lung cancer. J Clin Oncol 2024;42(21):2500-5. Abstract
Planchard D et al. Trastuzumab deruxtecan monotherapy in pretreated HER2-overexpressing nonsquamous non-small cell lung cancer: DESTINY-Lung03 part 1. WCLC 2024;Abstract OA16.05.
Riely GJ et al. Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). ESMO 2024;Abstract LBA56.
Ruiter G et al. Primary phase Ib analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in patients with HER2 mutation-positive NSCLC. WCLC 2024;Abstract PL04.04.
Sacher A et al. Divarasib single-agent long-term follow-up and atezolizumab combination treatment in patients with KRAS G12C-positive NSCLC. WCLC 2024;Abstract OA14.06.
Sands J et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study. J Clin Oncol 2025;43(10):1254-65. Abstract
Schram AM et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med 2025;392(6):566-76. Abstract
Smit EF et al. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol 2024;25(4):439-54. Abstract
Solomon BJ et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol 2024;42(29):3400-9. Abstract
Waterhouse DM et al. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. Lung Cancer 2024;196:107921. Abstract
Wolf J et al. Capmatinib in MET exon 14-Mutated non-small-cell lung cancer: Final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol 2024;25(10):1357-70. Abstract
Wu Y-L et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med 2024;390(14):1265-76. Abstract